[1. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3(3):315-22. DOI: 10.1016/S1388-9842(00)00141-0.10.1016/S1388-9842(00)00141-0]Search in Google Scholar
[2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46. DOI: 10.1136/hrt.2003.025270.10.1136/hrt.2003.025270195504017699180]Search in Google Scholar
[3. Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, et al. Relationship between early physician follow-up and 30-day read-mission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303(17):1716-22. DOI: 10.1001/jama.2010.533.10.1001/jama.2010.53320442387]Search in Google Scholar
[4. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30-41. DOI: 10.1038/nrcardio.2010.165.10.1038/nrcardio.2010.165303349621060326]Search in Google Scholar
[5. Aalbers J. New ESC heart failure guidelines with South African expert comment. Cardiovasc J Afr. 2012;23(5):295-6.]Search in Google Scholar
[6. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646-59. DOI: 10.1161/CIRCRESAHA.113.300268.10.1161/CIRCRESAHA.113.300268380629023989710]Search in Google Scholar
[7. Goidescu CM, Vida-Simiti LA. The Apelin-APJ System in the Evolution of Heart Failure. Clujul Med. 2015;88(1):3-8. DOI: 10.15386/cjmed-380.10.15386/cjmed-380450860926528040]Search in Google Scholar
[8. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc. 2008;40(10):3466-9. DOI: 10.1016/j.transproceed.2008.03.163.10.1016/j.transproceed.2008.03.16319100415]Search in Google Scholar
[9. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci. 2008;53(1):32-6. DOI: 10.2478/v10039-008-0024-x.10.2478/v10039-008-0024-x18635422]Search in Google Scholar
[10. Vida-Simiti L, Todor I, Stoia M, Gherman C, Goidescu C. Plasma levels of resistin predicts cardiovascular events. RRML. 2014;22(1):35-47. DOI: 10.2478/rrlm-2014-0011.10.2478/rrlm-2014-0011]Search in Google Scholar
[11. Vida-Simiti LA, Todor I, Stoia MA, Goidescu CM, Anton FP, Farcas AD. Better prognosis in overweight/obese coronary heart disease patients with high plasma levels of leptin. Clujul Med. 2016;89(1):65-71. DOI: 10.15386/cjmed-524.10.15386/cjmed-524477747127004027]Search in Google Scholar
[12. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91(5):434-40. DOI: 10.1161/01.RES.0000033522.37861.69.10.1161/01.RES.0000033522.37861.69]Search in Google Scholar
[13. Foldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun. 2003;308(3):480-5. DOI: 10.1016/S0006-291X(03)01424-4.10.1016/S0006-291X(03)01424-4]Search in Google Scholar
[14. Emam MN, Abo El gheit RE. Promoting effect of adipocytokine, apelin, on hepatic injury in caerulein-induced acute pancreatitis in rats: Apelin on AP-induced hepatic injury. Alexandria Journal of Medicine. DOI: 10.1016/j.ajme.2015.11.003. DOI: 10.1016/j.ajme.2015.11.003.10.1016/j.ajme.2015.11.003]Search in Google Scholar
[15. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8(4):355-60. DOI: 10.1016/j.ejheart.2005.10.007.10.1016/j.ejheart.2005.10.00716464638]Search in Google Scholar
[16. Zhang J, Ren CX, Qi YF, Lou LX, Chen L, Zhang LK, et al. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci. 2006;79(12):1153-9. DOI: 10.1016/j.lfs.2006.03.040.10.1016/j.lfs.2006.03.04016674982]Search in Google Scholar
[17. Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J. 2012;76(1):137-44. DOI: 10.1253/circj.CJ-11-0689.10.1253/circj.CJ-11-068922082814]Search in Google Scholar
[18. Soliman M, Arafah M. Apelin protect against multiple organ injury following hemorrhagic shock and decrease the inflammatory response. Int J Appl Basic Med Res. 2015;5(3):195-9. DOI: 10.4103/2229-516X.165377.10.4103/2229-516X.165377460658026539370]Search in Google Scholar
[19. Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204(1):222-8. DOI: 10.1016/j.atherosclerosis.2008.08.030.10.1016/j.atherosclerosis.2008.08.03018845302]Search in Google Scholar
[20. Heinonen MV, Laaksonen DE, Karhu T, Karhunen L, Laitinen T, Kainulainen S, et al. Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2009;19(9):626-33. DOI: 10.1016/j.numecd.2008.12.008.10.1016/j.numecd.2008.12.00819278844]Search in Google Scholar
[21. Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Calixto A, Geloneze B, et al. Apelin: a peptide involved in cardiovascular risk in hemodialysis patients? Ren Fail. 2012;34(5):577-81. DOI: 10.3109/0886022X.2012.668490.10.3109/0886022X.2012.66849022417287]Search in Google Scholar
[22. Wang M, Gupta RC, Rastogi S, Kohli S, Sabbah MS, Zhang K, et al. Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure. J Card Fail. 2013;19(7):509-16. DOI: 10.1016/j.cardfail.2013.05.004.10.1016/j.cardfail.2013.05.004370699523834927]Search in Google Scholar
[23. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol. 2006;553(1-3):222-8. DOI: 10.1016/j.ejphar.2006.09.034.10.1016/j.ejphar.2006.09.034181530117055480]Search in Google Scholar
[24. Jia ZQ, Hou L, Leger A, Wu I, Kudej AB, Stefano J, et al. Cardiovascular effects of a PEGylated apelin. Peptides. 2012;38(1):181-8. DOI: 10.1016/j.peptides.2012.09.003.10.1016/j.peptides.2012.09.00322986020]Search in Google Scholar
[25. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121(16):1818-27. DOI: 10.1161/CIRCULATIONAHA.109.911339.10.1161/CIRCULATIONAHA.109.91133920385929]Search in Google Scholar
[26. Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013;6(3):482-91. DOI: 10.1161/CIRCHEARTFAILURE.111.000077.10.1161/CIRCHEARTFAILURE.111.00007723519586]Search in Google Scholar
[27. Masri B, Knibiehler B, Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal. 2005;17(4):415-26. DOI: 10.1016/j.cell-sig.2004.09.018.]Search in Google Scholar
[28. Masri B, Morin N, Pedebernade L, Knibiehler B, Audigier Y. The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. J Biol Chem. 2006;281(27):18317-26. DOI: 10.1074/jbc.M600606200.10.1074/jbc.M60060620016679320]Search in Google Scholar
[29. Zhen EY, Higgs RE, Gutierrez JA. Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma. Anal Biochem. 2013;442(1):1-9. DOI: 10.1016/j.ab.2013.07.006.10.1016/j.ab.2013.07.00623872001]Search in Google Scholar
[30. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1] apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009;54(3):598-604. DOI: 10.1161/HYPERTENSIONAHA.109.134619.10.1161/HYPERTENSIONAHA.109.13461919597036]Search in Google Scholar
[31. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803-69. DOI: 10.1093/eurjhf/hfs105.10.1093/eurjhf/hfs10522828712]Search in Google Scholar
[32. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39 e14.10.1016/j.echo.2014.10.00325559473]Search in Google Scholar
[33. Foppa M, Duncan BB, Rohde LE. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Cardiovasc Ultrasound. 2005;3:17. DOI: 10.1186/1476-7120-3-17.10.1186/1476-7120-3-17118323015963236]Search in Google Scholar
[34. Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JA. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging. 2012;5(8):837-48. DOI: 10.1016/j.jcmg.2012.06.003.10.1016/j.jcmg.2012.06.003350120922897998]Search in Google Scholar
[35. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2015. Available from: http://www.r-project.org/.]Search in Google Scholar
[36. Miettinen KH, Magga J, Vuolteenaho O, Vanninen EJ, Punnonen KR, Ylitalo K, et al. Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul Pept. 2007;140(3):178-84. DOI: 10.1016/j.regpep.2006.12.004.10.1016/j.regpep.2006.12.00417223209]Search in Google Scholar
[37. Pitkin SL, Maguire JJ, Kuc RE, Davenport AP. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol. 2010;160(7):1785-95. DOI: 10.1111/j.1476-5381.2010.00821.x.10.1111/j.1476-5381.2010.00821.x293684920649580]Search in Google Scholar
[38. Liu HT, Chen M, Yu J, Li WJ, Tao L, Li Y, et al. Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention. Medicine (Baltimore). 2015;94(4):e449. DOI: 10.1097/MD.0000000000000449.10.1097/MD.0000000000000449460295325634182]Search in Google Scholar
[39. Kuklinska AM, Sobkowicz B, Sawicki R, Musial WJ, Waszkiewicz E, Bolinska S, et al. Apelin: a novel marker for the patients with first ST-elevation myocar-dial infarction. Heart Vessels. 2010;25(5):363-7. DOI: 10.1007/s00380-009-1217-3.10.1007/s00380-009-1217-320676956]Search in Google Scholar
[40. Chandrasekaran B, Kalra PR, Donovan J, Hooper J, Clague JR, McDonagh TA. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. J Card Fail. 2010;16(7):556-61. DOI: 10.1016/j.cardfail.2010.02.004.10.1016/j.cardfail.2010.02.00420610231]Search in Google Scholar